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It has become evident that somatic mutations in cancer-associated genes accumulate in the
normal endometrium, but spatiotemporal understanding of the evolution and expansion of
mutant clones is limited. To elucidate the timing and mechanism of the clonal expansion of
somatic mutations in cancer-associated genes in the normal endometrium, we sequence 1311
endometrial glands from 37 women. By collecting endometrial glands from different parts of
the endometrium, we show that multiple glands with the same somatic mutations occupy
substantial areas of the endometrium. We demonstrate that “rhizome structures”, in which
the basal glands run horizontally along the muscular layer and multiple vertical glands rise
from the basal gland, originate from the same ancestral clone. Moreover, mutant clones
detected in the vertical glands diversify by acquiring additional mutations. These results
suggest that clonal expansions through the rhizome structures are involved in the mechanism
by which mutant clones extend their territories. Furthermore, we show clonal expansions and
copy neutral loss-of-heterozygosity events occur early in life, suggesting such events can be
tolerated many years in the normal endometrium. Our results of the evolutionary dynamics of
mutant clones in the human endometrium will lead to a better understanding of the
mechanisms of endometrial regeneration during the menstrual cycle and the development of
therapies for the prevention and treatment of endometrium-related diseases.
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C

ancer is a collection of diseases characterized by
uncontrollable cellular growth and spread caused by
somatic mutations1,2. Genes whose mutations confer
selective growth advantages on cells are called cancer drivers or
cancer-associated genes3. With the advent of next-generation
sequencing technologies, large-scale cancer genome projects have
identiﬁed hundreds of cancer-associated genes4,5. The lifetime
incidence of cancer in different tissues is correlated with the
number of stem cell divisions in the corresponding tissues, suggesting that cancer-associated gene mutations randomly arise and
accumulate in human adult stem cells during life6,7. Recent studies have demonstrated that cancer-associated gene mutations
lurk not only in benign tumors but also in histologically normal
tissues8 such as bladder9, blood10, colon11–13, endometrium14–17,
esophagus18–20, liver21, lung22, skin23, and ureter24. Cells carrying
cancer-associated gene mutations are thought to manifest
increased cellular ﬁtness over their neighboring cells and to be
positively selected within normal tissues25. However, it remains to
be elucidated when and how mutant clones expand their territories in normal tissue. It is crucial to investigate the distribution
of cancer-associated gene mutations across time and space26.
Apart from higher primates, menstruation is quite rare in the
animal kingdom27. The human endometrium has a unique capability to cyclically regenerate and remodel throughout a woman’s
reproductive life. Histologically, the human endometrium is stratiﬁed into the stratum functionalis and the stratum basalis. The
functionalis is eroded during menstruation and regenerates from the
remaining basalis28. The highly regenerative nature of this tissue
poses risks for developing endometrium-related diseases such as
adenomyosis, endometrial hyperplasia, endometriosis, and endometrial and ovarian cancer in adult women. The normal endometrium can be a source of mutant clones that lead to the development
of endometrium-related diseases. By sequencing histologically normal endometrial glands, we and others have identiﬁed numerous
somatic mutations in cancer-associated genes, such as PIK3CA and
KRAS15–17. Individual glands carry distinct somatic mutations in
clonal states, verifying that the composition of each gland is
monoclonal29 but that gland-to-gland variation shapes the mosaiclike genomic composition of the uterine endometrial epithelium15,17.
Additionally, we found that several glands had identical mutation
proﬁles, even though we randomly collected glands by enzymatically
dissociating nearly the entire surgically resected part of the endometrium, implying the presence of mutant clones occupying certain
areas of histologically normal endometrium15.
The latest three-dimensional (3D) imaging analyses have
revealed that the morphology of the human endometrium is
much more complicated than previously believed30,31. In particular, plexus network structures of endometrial glands within the
basalis were discovered in humans30,31 but not in mice32,33.
Mutation proﬁling of endometrial glands guided by 3D imaging
techniques can help illuminate mechanisms by which somatic
mutations spread within the endometrial epithelium.
In this work, we perform target-gene sequencing, whole-exome
sequencing (WES), and whole-genome sequencing (WGS) for 1311
endometrial glands from 37 women across a wide range of ages.
Combined with the estimation of chronological ages at which
genome events such as clonal expansions and somatic copy number
alterations occurred, our sequencing analyses preserving the spatial
information of endometrial glands provide fundamental clues to
understand the spatiotemporal dynamics of clones with cancerassociated gene mutations in the normal endometrium.
Results
Cancer-associated gene mutations in normal endometrial
glands. We conducted target-gene sequencing of 112 genes in 891
2

normal endometrial glands from the uteri of 32 subjects ranging
in age from 21 to 53 years old (Fig. 1a, Supplementary Table 1
and Supplementary Data). More than half of the normal endometrial glands acquired numerous somatic mutations in genes
that are frequently mutated in endometrial cancer and
endometriosis-associated ovarian cancer (Fig. 1b and Supplementary Fig. 1). The most frequently mutated genes included
PIK3CA (15.6%), KRAS (10.9%), FBXW7 (8.1%), PIK3R1 (7.1%),
and PPP2R1A (6.7%) (Fig. 1c). The mutant allele frequencies
(MAFs) of these mutations were close to 0.5, indicating their
clonal expansion within the glands (Fig. 1d). Moreover, the MAFs
of the mutations exhibited a trimodal distribution presumably
composed of subclonal mutations (<0.25), clonal mutations
(≥0.25), and clonal mutations with allelic imbalance, such as
subsequent loss of the wild-type allele (≥0.75) (Fig. 1e). 61.8%
(=551/891) and 50.1% (=446/891) of glands harbored high and
low MAF SNVs, respectively. The presence of both clonal and
subclonal mutations suggests that a cell clonally expands to form
an endometrial gland, and the clone then acquires additional
diversifying mutations. KRAS mutations in 15 endometrial glands
exhibited allelic imbalance favoring mutant alleles (MAF ≥0.8,
binomial test P < 10−5).
Somatic mutations accumulate with age and cumulative
number of menstrual cycles (CNMCs). To dissect active mutational processes, we classiﬁed the somatic single-nucleotide variants (SNVs) with high MAF (≥0.25) into 96 mutation classes
constituted by the six pyrimidine substitutions (C>T, C>A, C>G,
T>C, T>G, and T>A) in combination with the ﬂanking 5′ and 3′
bases (Fig. 1f). We explored mutational signatures characterizing
the mutational processes operative in normal endometrial glands,
where the spectrum of somatic SNVs with high MAF was ﬁtted to
a set of the Catalogue of Somatic Mutations in Cancer (COSMIC)
mutational signatures34 (“Methods”). Three mutational signatures (SBS1, SBS5, and SBS18) were signiﬁcantly overrepresented (Fig. 1g). SBS1 is a clock-like mutation signature
characterized by C>T transitions at CpG motifs, indicative of the
deamination of methyl-cytosines35. SBS5 is another clock-like
mutation signature with unknown etiology36. SBS18, represented
by C>A transversions, has been attributed to DNA damage
induced by reactive oxygen species37.
We calculated the burden of somatic mutations for each
subject over glands. The burden varied substantially among the
subjects (Fig. 2a and Supplementary Fig. 1). We examined
whether the burden of somatic mutations was associated with the
clinical characteristics of the subjects. The burden of somatic
SNVs with high MAF showed strong linear relationships with age
(Pearson’s correlation coefﬁcient, r = 0.79; P = 7.5 × 10−8) and
CNMCs (r = 0.81; P = 2.4 × 10−8) (Fig. 2b). CNMCs explained
the burden of somatic SNVs with high MAF better than age,
probably because menarche was negatively associated with the
burden after adjustment for age (r = −0.30; P = 0.09) (Fig. 2c,
Supplementary Fig. 2a). Moreover, both age and CNMCs were
signiﬁcantly associated with the burden of C>T transitions at
CpG motifs (Fig. 2d and Supplementary Fig. 2d) and with the
burdens of C>T, C>A, C>G, and T>C substitutions, but not with
the burden of T>G or T>A substitutions (Fig. 2e and
Supplementary Fig. 2e), reminiscent of the abovementioned two
mutational signatures with clock-like properties (SBS1 and SBS5).
Next, we examined the burden of driver mutations that were
deﬁned as non-silent SNVs and short insertions and deletions
(indels) with high MAF in cancer-driver genes (ARID1A,
CTNNB1, FBXW7, KRAS, PIK3CA, PIK3R1, PPP2R1A, PTEN,
and TP53). The burden of driver mutations was signiﬁcantly
associated with age (r = 0.63; P = 9.9 × 10−5) and CNMCs
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(r = 0.69; P = 1.3 × 10−5) (Supplementary Fig. 3). Again, CNMCs
explained the burden of driver mutations better than age, because
age of menarche showed a signiﬁcant negative correlation after
the adjustment for age (r = −0.50; P = 3.4 × 10−3). The effects of
parity, body mass index (BMI), pack years of smoking and disease
status were not signiﬁcantly associated with the burdens of
somatic SNVs with high MAF and driver mutations after the
adjustment for age (Supplementary Figs. 2b, c and 3).
The average age and CNMCs of patients with KRAS mutations
exhibiting allelic imbalance (MAF ≥ 0.8) were higher (P = 0.041
and P = 0.021, respectively; Wilcoxon rank-sum test). Additionally, mutations exhibiting allelic imbalance were overrepresented
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in patients with endometriosis (P = 0.012; Fisher’s exact test).
Further studies are needed to validate the associations between
KRAS mutations exhibiting allelic imbalance and clinical
variables.
Strong positive selection acting on cancer-associated genes. The
distributions of the cancer-associated gene mutations in normal
endometrial glands were similar to those in cancers based on the
COSMIC database38 (Fig. 3a–f and Supplementary Fig. 4).
Additionally, nonsilent mutations predominated over silent
mutations in the cancer-associated genes. Therefore, we assessed
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Fig. 1 Landscape of somatic mutations in normal endometrial glands. a An outline ﬂowchart of isolation of single endometrial glands. First, the samples
were collected from endometrial biopsies using suction catheters or endometrial curettage. Second, endometrial tissues digested with collagenase to
separate glands from stroma. Third, the solution of collagenase-digested tissue was poured into a cell strainer. The epithelial cell glands remaining on the
strainer were transferred into a cell culture dish. Finally, individual glands were picked up precisely under a microscope. Scale bar in microscopic images,
100 µm. b Heatmap of the prevalence of nonsilent somatic mutations in 891 normal endometrial glands from the uteri of 32 subjects. Nonsilent mutations
are color-coded as follows: missense SNVs (red), nonsense SNVs (blue), splice-site SNVs (yellow), in-frame indels (green) and frameshifting indels
(black). Color density indicates the MAF of each somatic mutation. c Bar charts representing proportions of endometrial glands with somatic mutations in
15 cancer-associated genes stacked by mutation type: SNVs (black), indels (gray), and both (white). d Box-whisker plots showing distributions of the MAFs
of somatic mutations on the 15 genes. The number of mutations in each of the 15 genes (n), from top to bottom, is 139 (PIK3CA), 97 (KRAS), 98
(ARHGAP35), 72 (FBXW7), 66 (PIK3R1), 60 (PPP2R1A), 32 (PTEN), 26 (KMT2C), 26 (TAF1), 25 (ARID1A), 24 (FGFR2), 24 (PLXNB2), 18 (CHD4), 18 (ZFHX3),
and 11 (TP53). Box plots show the minima (leftmost dot), the maxima (rightmost dot), the median (middle line) and the ﬁrst and third quartiles (boxes),
whereas the whiskers show 1.5× the interquartile range (IQR). e Density plot showing trimodal distributions of the MAFs of all the identiﬁed somatic
mutations. The vertical line at an MAF of 0.25 represents the threshold for dichotomizing mutations into low- and high-MAF mutations. f Lego plot
depicting the mutation spectrum of somatic SNVs with high MAF in normal endometrial glands. g Bar chart representing the results of Bayesian inference
by using sigﬁt to determine the contribution of the COSMIC mutational signatures to somatic SNVs with high MAF. Data are presented as the estimated
contributions of signiﬁcant mutational signatures and the lower and upper limits of the 90% highest posterior density interval. The inset is a doughnut
chart summarizing the contributions of three signiﬁcant mutational signatures (SBS1, SBS5, and SBS18). The number of high MAF SNVs (n) used for the
analysis is 810. Source data are provided as a Source data ﬁle.

whether the somatic mutations in cancer-associated genes were
under positive and negative selection in normal endometrial
glands based on the dN/dS ratio39 (“Methods”). First, we evaluated the extent of selection acting on a set of genes. The dN/dS
ratios of missense mutations for all 112 targeted genes, 48 genes
in the Cancer Gene Census40, and 15 genes in the pangynecologic cancer-associated genes41 were 3.13 (95% conﬁdence interval [CI], 2.38-4.12; P = 4.4 × 10−16), 4.92 (95% CI,
3.38–7.16; P < 10−16), and 14.5 (95% CI, 7.20–29.2;
P = 7.1 × 10−14), respectively (Fig. 3g). The dN/dS ratios of
nonsense mutations for these sets of genes were 6.15 (95% CI,
4.35–8.68; P < 10−16), 5.88 (95% CI, 3.63–9.53; P = 6.7 × 10−13)
and 11.1 (95% CI, 4.95–24.7; P = 4.7 × 10−9), respectively
(Fig. 3g). Notably, the extent of positive selection was strongest in
the pan-gynecologic cancer-associated genes. According to the
dN/dS ratios, up to 93.1% of the missense and 91.0% of the
nonsense mutations in the pan-gynecologic cancer-associated
genes were estimated to be drivers with strong selective advantages in the normal endometrium. On the contrary, the dN/dS
ratios of missense and nonsense mutations in genes other than
cancer-associated genes were 0.98 (95% CI, 0.63–1.51; P = 0.91)
and 1.20 (95% CI, 0.52–2.75; P = 0.67), respectively (Fig. 3g). This
result suggests that the mutations in the non-cancer-associated
genes were selectively neutral (passengers).
Next, we explored signals of selection at the level of individual
genes. Missense mutations of KRAS, PIK3CA, PPP2R1A, FBXW7,
PTEN, PIK3R1, TP53, FGFR2, ARHGAP35, and PLXNB2
exhibited strong signals of positive selection (false discovery rate
(FDR) < 0.1; Benjamini–Hochberg procedure) (Fig. 3h). In
addition, nonsense substitution rates in ARHGAP35, PTEN,
PIK3R1, FBXW7, ARID1A, ARID5B, TAF1, ZFHX3, and KMT2C
signiﬁcantly exceeded synonymous substitution rates (FDR < 0.1)
(Fig. 3h). Remarkably, two representative oncogenes, KRAS and
PIK3CA, showed biased signs of positive selection toward the
excess of missense substitution rates without observing nonsense
substitutions (Fig. 3i). Tumor suppressor genes presented several
patterns: PTEN, FBXW7, and PIK3R1 showed excesses of both
missense and nonsense substitution rates. ARHGAP35 and
ARID1A showed biased signs toward excess nonsense substitution
rates, while missense substitutions were predominant in
PPP2R1A and TP53 (Fig. 3i).
Although we randomly collected endometrial glands from the
entire uterus, 15 out of 32 subjects had at least one pair of glands
that identically shared multiple high-MAF mutations (Supplementary Fig. 5). Glands from two subjects aged 47 showed higher
4

burdens of identically shared multiple high-MAF mutations.
Seven out of 27 glands from Subject 27 harbored identical KRAS
(p. G12C) and PIK3CA (p. G118D) mutations. Four out of
16 glands from Subject 28 shared KRAS (p. G12D) and SPEG
(p. A2522=) mutations. These ﬁndings imply that glands with the
same clonal origin spread over a wide area of the endometrium,
particularly in aged women.
Spatially resolved single endometrial gland sequencing. We
conducted target-gene sequencing for spatially resolved single
endometrial glands, in which surgically resected specimens of
normal endometrium from four subjects were subdivided into
grids, and endometrial glands were collected from the grids. Thus,
spatial information of each gland was retained at the grid level
(Figs. 4 and 5, Supplementary Fig. 6 and Supplementary Table 2).
We sought informative mutations that were shared among multiple endometrial glands. Then, we performed hierarchical clustering of the MAF proﬁles of the informative mutations.
We divided the endometrium from a 38-year-old subject with
endometriosis (Subject 33) into 24 grids with 3.5 mm squares and
extracted three glands from each grid (Fig. 4a). We identiﬁed two
clusters characterized by PIK3CA (p.E545A) and KIF26A
(p.P326L) and by KRAS (p.G12S) and PIK3CA (p.E542V).
The glands in each cluster were located within the same grid
(Fig. 4b, c).
For a subject aged 41 years with myoma uteri (Subject 34), we
examined ﬁve glands from each of 24 grids with 5 mm squares
(Fig. 4d). We detected four clusters of glands with distinct
mutation proﬁles (Fig. 4e, f). The largest cluster characterized by
two mutations (ZFHX4 [p. A527V] and PPP2R1A [p.S219L])
occupied ﬁve adjacent grids (3, 11, 12, 14, and 15), spanning
~2 cm in the largest diameter. Glands carrying only ZFHX4
(p.A527V) were present in the central region (grids 7 and 12)
linking the abovementioned ﬁve grids. We further investigated
the clonal origin of these glands with a larger number of somatic
mutations by WES. The glands with only ZFHX4 (p.A527V)
shared additional somatic mutations with the glands harboring
both ZFHX4 (p.A527V) and PPP2R1A (p.S219L) (Supplementary
Fig. 6e). The phylogenetic tree obtained by WES suggests that the
glands in these two groups have a common ancestral clone
harboring ZFHX4 (p.A527V) from which two descendant clones
diversiﬁed, one of which acquired PPP2R1A (p.S219L) and then
spread to the broad area (Fig. 4g).
The anterior and posterior walls of the endometrium from a
46-year-old subject with cervical carcinoma in situ (Subject 35)

NATURE COMMUNICATIONS | (2022)13:943 | https://doi.org/10.1038/s41467-022-28568-2 | www.nature.com/naturecommunications

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28568-2

a

b
r = 0.79, P = 7.5 × 10-8

Value
Burden of high MAF SNVs

Burden of high MAF SNVs

C>T
C>A
C>G
Age
T>C
CNMC
T>G
T>A Pack-years

53
480
26

21
96
0

1.0

r = 0.81, P = 2.4 × 10-8

1.0

0.5

0.0
20

30

40

50

100

200

Age

c

0.5

Burden of high MAF SNVs

Subject 2
Subject 4
Subject 16
Subject 6
Subject 11
Subject 1
Subject 3
Subject 9
Subject 7
Subject 17
Subject 5
Subject 8
Subject 24
Subject 15
Subject 14
Subject 10
Subject 20
Subject 30
Subject 25
Subject 13
Subject 23
Subject 12
Subject 21
Subject 29
Subject 19
Subject 18
Subject 22
Subject 31
Subject 28
Subject 26
Subject 32
Subject 27

400

Adjusted for age
r = -0.30, P = 0.09

0.0
Age
CNMC
Pack-years

300

CNMC

r = 0.01, P = 0.971

0.9
0.6
0.3
0.0
10

11

12

13

14

15

0.0

Menarche (age)

1.0

2.0

Parity (n)

e

d
C>T substitutions
in the CpG context

0.4

0.2

0.0
100

200

300

CNMC

400

Burden of high MAF SNVs

Burden of high MAF SNVs

r = 0.42, P = 0.017

C>T

C>A

C>G

T>C

r = 0.64, P = 7.1 × 10-5 r = 0.53, P = 2.0 × 10-3 r = 0.50, P = 3.7 × 10-3 r = 0.56, P = 8.3 × 10-4

T>G

T>A

r = 0.18, P = 0.318

r = 0.06, P = 0.735

0.6

0.4

0.2

0.0
100 200 300 400

100 200 300 400

100 200 300 400

100 200 300 400

100 200 300 400

100 200 300 400

CNMC

Fig. 2 Burden of somatic mutations accumulates with age and CNMCs. a Bar charts showing the burdens of somatic SNVs with high MAF for 32 subjects
stacked by the six pyrimidine substitutions (C>T, C>A, C>G, T>C, T>G, and T>A). The burden is deﬁned as the number of high-MAF SNVs per Mbp
sequenced. Multiple glands from an individual subject are pooled. Subjects are sorted in ascending order according to mutation burden. The heatmap
below the bar charts represents age, CNMCs, and pack-years of cigarette smoking for the 32 subjects. b Linear relationships of age and CNMCs with the
burden of somatic SNVs with high MAF. c Linear relationships of age of menarche and number of parities with the burden of somatic SNVs with high MAF
after adjustment for age. d Linear relationship of CNMCs with the burden of C>T transitions at CpG motifs. e Linear relationships of CNMCs with
the burdens of the six pyrimidine substitutions. b–e Pearson’s correlation coefﬁcient (r) and the statistical signiﬁcance level (P) based on two-tailed test
are shown. Unadjusted P-value is shown. The slope of a linear regression line (solid line) with 95% CI (shaded area as error band) is plotted. Source data
are provided as a Source data ﬁle.

were resected. Each of them was divided into 24 grids with 4 mm
squares (Fig. 4h). The sequencing of three glands from each grid
showed six and nine clusters with distinct mutations in the
anterior and posterior walls, respectively (Fig. 4i–k). Glands in
nine clusters were distributed among multiple neighboring grids,
suggesting a high level of mosaicism in the endometrium of this
subject. Glands in six clusters had the same mutation of FGFR2
(p.S252W). However, WES showed that the glands in different
clusters did not share any mutations other than FGFR2
(p.S252W) (Supplementary Fig. 6f). Additionally, glands in these
six clusters were localized in spatially separated regions of the
endometrium: Cluster 3 was distributed in the center of the
anterior wall, cluster 12 was in the upper right of the posterior
wall, and clusters 8, 13–15 were in the lower left of the posterior
wall (Fig. 4i). It is not likely that the FGFR2 mutation initially
occurred in a single ancestral clone and the ancestral clone
expanded to these three separated regions as depicted by the
phylogenetic tree (Fig. 4l), because glands with the FGFR2
mutation were not detected in regions connecting the three

regions. Therefore, a plausible explanation may be that at least
three mutational events of the FGFR2 mutation occurred
independently in the three separated regions of the endometrium
and the mutant clones diversiﬁed at each region by acquiring
region-speciﬁc mutations.
More intensive screening was conducted in the endometrium
from a 50-year-old subject with myoma uteri, where the 1 cmsquare region was divided into four grids (A to D), and one of
them (A) was further partitioned into four subgrids (A-I to A-IV)
(Fig. 5a, Supplementary Fig. 6g–i). We extracted 13 or 15 glands
from each of the subgrids and 20 glands from the remainder of
the grids (B, C, and D). We identiﬁed ﬁve clusters: two were
limited to within a grid or subgrid, and the other three were
prevalent among multiple grids and subgrids (Fig. 5b, c). Two
clusters (1 and 3) accounted for 18 glands spreading across three
grids (B, C, and D) and one subgrid (A-IV) and 16 glands
spreading across two grids (C and D), respectively. Cluster 3 had
a frameshift insertion in PTEN with high MAF (>0.5), implying
an allelic imbalance at PTEN, which is known to occur frequently
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in endometrial carcinoma42. Using WGS, we conﬁrmed that
glands in the same clusters originated from common ancestral
clones (Fig. 5d, e). Additionally, we identiﬁed two arm-level copyneutral loss-of-heterozygosity (CN-LOH) events at chromosomes
3 and 10 in all glands of cluster 3 (Fig. 5f and Supplementary
Fig. 7). As reﬂected in the branch lengths of the phylogenetic tree,
the number of private mutations unique to single glands was
larger in cluster 1 than in cluster 3 (Fig. 5d, e). We leveraged the
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intracluster heterogeneity to infer the chronological ages at which
genomic events emerged in the endometrium (“Methods”). The
most recent clonal expansions of clusters 1 and 3 were estimated
to have occurred at the ages of 38.3 (95% CI, 37.1–39.6) and 49.2
(95% CI, 48.9–49.5), respectively (Fig. 5g). This implies that stem/
progenitor cells giving rise to glands of cluster 1 had spread their
territories for more than 10 years and diverged by acquiring
mutations, which led to local variability. In sharp contrast, the
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Fig. 3 Localization and positive selection of cancer-associated gene mutations in normal endometrial glands. a–f Lollipop plots showing the locations of
the identiﬁed somatic mutations in a PIK3CA, b KRAS, c ARHGAP35, d FBXW7, e PIK3R1, and f PPP2R1A along with known domain structures of the proteins
encoded by these genes. Numbers refer to amino acid residues. The heights of the lollipops correspond to the number of mutations at each amino acid
residue. Black bar charts indicate the number of somatic mutations deposited in the COSMIC database. g Estimated values of the dN/dS ratios for
missense and nonsense mutations acting on a set of genes. The dN/dS ratios of missense mutations for all 112 targeted genes, 48 genes in the Cancer
Gene Census (CGC), 15 genes in the pan-gynecologic cancer-associated genes (Pangyn) and non-cancer-associated genes. Non-cancer-associated genes
were deﬁned as a list of genes by excluding the CGC and Pangyn genes and ARHGAP35 from 112 targeted genes. The numbers (n) of missense, nonsense,
and synonymous substitutions are 543, 76, and 56, respectively, in all 112 genes; 444, 38, and 29, respectively, in the CGC; 385, 23, and 8, respectively, in
the Pangyn; and 81, 7, and 27, respectively, in the non-cancer-associated genes. Data are presented as the estimates of the dN/dS ratio and their 95% CIs.
h Estimated values of dN and dS for missense and nonsense mutations at the level of individual genes. The dN and dS values are shown rather than the dN/
dS ratios because the dS values for some genes were zero because of the absence of synonymous substitutions. Signiﬁcant genes at FDR < 0.1 are
shown. i Scatterplot of the estimated dN − dS values for missense mutations against those for nonsense mutations in 16 cancer-associated genes in
(h). Oncogenes: red, tumor suppressor genes: blue, and other genes: gray. Source data are provided as a Source data ﬁle.

clone-producing glands of cluster 3 had undergone rapid growth
within a short period. We investigated whether the CN-LOHs at
chromosomes 3 and 10 contributed to the rapid expansion by
examining the MAF proﬁles of public SNVs that were shared
among all the glands in the cluster and located in the regions
affected by the CN-LOHs (Fig. 5h). The rationale behind this
analysis is that the MAFs of mutations that occurred before a CNLOH are expected to become predominant, whereas mutations
that occurred subsequently are expected to be half as prevalent
because they are present in one of the two copies of the duplicated
chromosome. Therefore, we can estimate the timing of the CNLOH based on the proportion of public mutations with
predominant status to the overall public mutations in the CNLOH region43,44. Surprisingly, the burden of somatic SNVs that
preceded the CN-LOH at chromosome 10 was lower than that of
SNVs that occurred subsequently. On the other hand, the burden
of somatic SNVs that preceded the CN-LOH at chromosome 3
exceeded that of those that occurred subsequently. Consequently,
the CN-LOHs at chromosomes 10 and 3 were estimated to occur
at the ages of 17.3 (95% CI, 11.7–22.8) and 35.5 (95% CI,
30.8–40.1), respectively (Fig. 5i, j), both decades earlier than the
most recent clonal expansion.
3D imaging of normal endometrial glands. To elucidate the
mechanisms by which endometrial glands with the same clonal
origin expanded across spatially distant regions, we performed 3D
imaging analysis on normal proliferative endometrial tissues from
four middle-aged women who underwent hysterectomy due to
gynecological diseases (Supplementary Table 3) by using a
recently developed tissue clearing technique combined with lightsheet ﬂuorescence microscopy31,45. By examining continuous
tomographic images, we visualized the plexus structures linking a
set of glands with their root at the basal layer (Fig. 6a, b and
Supplementary Video 1). Speciﬁcally, the glandular structure at
the bottom of the endometrium ran horizontally along the
muscular layer, similar to a rhizome of grass (hereinafter called
the “rhizome structure”), and several branches rose from the
rhizome structure toward the luminal epithelium (Fig. 6c and
Supplementary Video 1). The rhizome structures expanded linearly rather than radially. These properties were found in all four
cases, suggesting that the presence of rhizome-sharing glands is
common in middle-aged women (Supplementary Fig. 8).
To quantify the space occupied by a continuous set of rhizome
structures and glands derived from the rhizome, we selected a
representative rhizome from each patient. The number of
rhizome-sharing glands ranged from 4 to 19 (Supplementary
Fig. 8a–d). We determined the XYZ coordinates of the tips of
rhizome-sharing glands to measure the longest distance between
glands and the area occupied by the glands (Fig. 6d and
Supplementary Fig. 8e–l). The rhizome-sharing glands reached

a length of 1.3–3.8 mm and occupied an area of 0.3–4.7 mm2,
indicating that they occupied a substantial part of the
endometrium.

WGS for selectively isolated endometrial glands based on 3D
images. To analyze the genomes of rhizome structures and the
vertical glands derived from them, we examined 70 serial cryosections (12 µm thick) from the proliferative-phase endometrium
of a 43-year-old woman who underwent hysterectomy for
endometriosis (Fig. 7a–c). We detected two independent groups
of glands that were in close proximity but separated from each
other; the ﬁrst group comprised rhizome G1 and vertical glands
G2–G7, and the second group comprised rhizome G8 and vertical
glands G9–G12 (Fig. 7b, c and Supplementary Fig. 9). Additionally, we found a single vertical gland (G13) that was independent of the two gland groups. Then, the 3D image was
reconstructed to validate the spatial locations and continuity of
the 13 glands (Fig. 7d and Supplementary Video 2). Guided by
the 3D image analysis, we microdissected the 13 glands for WGS
(Fig. 7a). The WGS showed that the ﬁrst and second groups
shared different sets of somatic mutations, but G13 did not share
mutations with other glands, suggesting that each of the groups
comprising a rhizome and vertical glands originated from a
unique mutant clone (Fig. 7e). The proﬁle for cancer-associated
gene mutations also showed a group-speciﬁc segregation pattern
(PIK3CA [p. E453K] in the ﬁrst group, PTEN [p. Y188 X] and
PIK3R1 [p. R574del] in the second group, and KRAS [p. G12V] in
G13) (Fig. 7f).
We investigated the clonal populations in the 13 glands by
using PyClone46. The somatic SNVs were classiﬁed into 11
clusters (Supplementary Fig. 10a). Two clusters consisted of
public mutations that were shared among all the glands in either
of the two groups. Six clusters encompassed partially shared
mutations among some glands in a group. Three clusters
contained private mutations unique to single glands. Then, we
performed clone ordering of the identiﬁed clusters with
ClonEvol47. The ﬁsh plots showed that ancestral clones (A and
G) characterized by public mutations initially expanded, and then
their descendant clones characterized by partially shared or
private mutations emerged (Fig. 7g). Some of the partially shared
mutations that reached ﬁxation in vertical glands were observed
in subclonal states in their respective rhizomes (Fig. 7g, h). The
most recent clonal expansions in the ﬁrst and second groups were
estimated to have occurred at ages 34.5 (95% CI, 33.0–36.0) and
35.1 (95% CI, 33.7–36.6), respectively (Fig. 7i). These results
imply that the two rhizome structures were independently shaped
by clonal expansions of ancestral clones approximately 9 years
ago, and stem/progenitor cells with self-renewal and differentiation capabilities residing in different zones of the rhizomes
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acquired their own mutations and subsequently gave rise to
vertical glands.
Next, we focused on the clonal evolution of three glands
(G3–G5) that diverged near the center of the functional layer
(Fig. 7c). From the background of an ancestral clone (A), two
distinct mutant clones (C and D) proliferated to generate the
lower glands (G3 and G4, respectively). Both of these mutant
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clones coexisted in subclonal states in the upper gland (G5)
(Fig. 7g, h). Speciﬁcally, the MAFs of mutations observed in either
G3 or G4 were close to 0.5 in the corresponding glands but
approximately 0.25 in G5 (Supplementary Fig. 10b). These results
suggest that G3 and G4 independently rose from the rhizome
(G1), and G5 was formed by the conﬂuence of G3 and G4 on
their way to the luminal side.
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Fig. 4 Sequencing of spatially resolved single endometrial glands. The results for three subjects are represented in different panels: a–c 38-year-old
woman with endometriosis (subject 33), d–g 41-year-old woman with myoma uteri (subject 34) and h, i 46-year-old woman with cervical carcinoma in situ
(subject 35). The anterior and posterior walls of the endometrium from subject 35 were used. a, d, h Macroscopic images of uterine tissue samples
obtained from three subjects who underwent a total hysterectomy, in which the endometrium is highlighted in light blue. Schematic layouts show the
partitioning of the resected endometrium into square grids with their identiﬁcation numbers. R: right side of uterus. L: left side of uterus. b, e, i Clusters
detected by hierarchical clustering analyses mapped by projecting on the schematic layout of the endometrium sample. Pie charts show numbers and
proportions of glands grouped in the clusters. The colors of clusters are the same as in (c, f, j, k). c, f, j, k Hierarchical clustering of the mutation proﬁles of
endometrial glands based on MAFs for a set of high-MAF mutations shared among at least two glands in the target-gene sequencing. Glands marked with
an asterisk were used for WES. Color density indicates the MAF of each somatic mutation. g, l Phylogenetic tree for binary mutation proﬁles based
on WES.

Discussion
Here, we showed that the genomes of normal endometrial glands
were suffused with mutations caused by clock-like mutational
processes and oxidative stress. The burdens of substitutions
relevant to these mutation signatures were observed to increase
with age and CNMCs, which is consistent with recent studies16,17.
The highly regenerative nature of the endometrium may be
involved in the accumulation of somatic mutations. Most of the
genes showing evidence of positive selection in the normal
endometrium are frequently mutated in endometrial cancer39,48,
suggesting that mutations in the genomes of endometrial cancer
are inherited from the normal endometrium. Although cancerassociated gene mutations are pervasive in endometrial glands,
~3% of women are estimated to be diagnosed with uterine cancer
during their lifetime, suggesting that cancer-associated gene
mutations alone are not sufﬁcient to initiate cancer. DNA quality
control pathways are thought to be permissive of mutagenesis in
normal cells because the repair of DNA lesions requires time and
cellular resources; therefore, cells maintaining comprehensive
repair would sacriﬁce their cellular survival49. Moreover, there is
a possibility that some cancer-associated gene mutations might
enhance cellular proliferation and beneﬁt endometrial regeneration after menstruation, as shown in liver regeneration50.
We demonstrated that glands originating from the same
mutant clones were distributed across spatially separated regions
of the endometrium. The extent of the colonization by mutant
clones differed across endometrium samples. In the endometrium
from a 50-year-old woman, two distinct mutant clones occupied
substantial areas, one of which had a frameshift insertion in
PTEN accompanied by arm-level CN-LOHs and had undergone
rapid clonal expansion. Seemingly, this clone might have been
only a few steps away from turning malignant. However, there
was a long latency between the CN-LOHs and the most recent
clonal expansion, implying that even arm-level copy number
alterations are not sufﬁcient to immediately trigger tumorigenesis.
Our ﬁnding corroborated recent studies in kidney and lung
cancers showing structural rearrangements that occurred during
childhood and adolescence, many decades before disease
diagnosis43,44. Nongenetic factors such as epigenetic alterations
and complex interplays with stromal cells, hormonal inﬂuence
and the immune system may also contribute to the transformation of normal cells into malignant cells8.
The missing piece is how incipient mutant clones colonize
normal tissues26. Clonal expansions in normal tissues may be
constrained by anatomical features of the corresponding tissues;
therefore, tissue-speciﬁc mechanisms should be elucidated51.
Clonal expansion by crypt ﬁssion is a striking anomaly in the
unraveled tissue-speciﬁc mechanism, where mutations that occur
in a colonic stem cell are ﬁxed in a whole crypt by monoclonal
conversion and then the wholly mutated crypt divides into two
mutated daughter crypts52,53. To approach the endometriumspeciﬁc mechanisms of clonal expansion, we leveraged 3D imaging analysis to inspect the continuum of glandular epithelium in

the normal human endometrium. Although the presence of basal
glands running horizontally and parallel to the luminal surface
has been documented since at least the 1920s54,55, plexus
rhizome-like structures, in which multiple vertical glands were
linked with the horizontal basal gland, were discovered only
recently with the advent of 3D imaging analyses30,31. Tempest
et al. have proposed that rhizome-structures assist self-preservation, self-renewal, and scarless regeneration of the human endometrium as a niche of endometrial epithelial stem/progenitor
cells30. In this study, we demonstrated that the continuum of a
rhizome and vertical glands had a monoclonal origin. Taking into
consideration the widely accepted idea that the functional layer
regenerates from the glands remaining in the basalis after
menstruation56,57, we propose a plausible model of clonal
expansion in the normal endometrium. Residual basal glands
extend horizontally along the muscular layer to shape monoclonal
rhizomes. Then, the rhizome gives rise to vertical glands that have
the same clonal origin. Some rhizome structures persist for many
cycles of repair and regeneration during menstrual cycles and
further expand their territories. Several rounds of clonal conversion might occur when new clones acquire selective advantages by cancer-associated gene mutations. At the same time,
stem/progenitor cells resident in the rhizome acquire unique
mutations, which leads to local variability of the vertical glands.
The clonal expansion through rhizome structures proposed in
this study is by no means the only mechanism. Since rhizome
structures are thought to be speciﬁc to animals that
menstruate30–33, the development of rhizome structures and
clonal expansion through rhizome structures might be byproducts of the evolution of menstruation. The elucidation of the
mechanisms of clonal expansion in both menstruating and
nonmenstruating species will provide fundamental clues for
understanding homeostatic tissue remodeling and oncogenesis.
Another important ﬁnding is the admixed genomic composition
of branched glands, which implies that two glands from a rhizome join together and open into the superﬁcial layer in a
bottom-up manner. A previous study reported individual endometrial glands containing both cytochrome c oxidase (CCO)positive and CCO-negative cells30. Our ﬁndings give an important perspective on the monoclonal and polyclonal cellular
compositions of single endometrial glands.
The mechanisms of rhizome structure formation in the human
endometrium are totally unknown. Anatomical, embryological,
and physiological studies are required to elucidate when and how
the rhizome structures develop. For this purpose, it will be helpful
to clarify the spatial relationship between rhizome structure and
vascular network by 3D imaging. The biological and medical
signiﬁcance of the rhizome structures also remains obscure. We
speculate that the rhizome structures act as a double-edged
sword. The presence of the rhizome structures might be beneﬁcial
for post-menstrual endometrial repair by protecting the endometrial stem/progenitor cells from shedding at the menstrual
phase30,31. We presume that clones with cancer-associated gene
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mutations may confer a proliferative advantage and contribute to
stable tissue regeneration by expanding the area of rhizome
structure. On the other hand, the rhizome structures might confer
deleterious effects to predispose women to endometrium-related
diseases by accumulating cancer-associated gene mutations. A
recent study showed that adenomyosis and histologically normal
endometrium adjacent to the adenomyotic lesions had identical
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KRAS hotspot mutations, suggesting that KRAS-mutated adenomyotic clones originate from normal endometrium58. In the WES
study for a patient with ovarian clear cell carcinoma with concurrent endometriosis, we showed that many somatic mutations
including cancer-associated gene mutations were shared among
epithelium samples from uterine endometrium, endometriotic
lesions distant from and adjacent to the carcinoma, and the
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Fig. 5 Spatiotemporal evolution of mutant clones in the normal endometrium. a A macroscopic image of a part of a tissue sample of the uterus obtained
from a 50-year-old woman (subject 36) with myoma uteri who underwent a total laparoscopic hysterectomy. A part of the endometrium enclosed by the
dashed yellow line was intensively analyzed. A schematic layout represents partitioning of the resected endometrium into square grids with their
identiﬁers. b Clusters detected by hierarchical clustering analysis are mapped by projection onto the schematic layout of the endometrium sample. Pie
charts show the numbers and proportions of glands grouped in the clusters. The colors of the clusters are the same as in (c). c Hierarchical clustering of
mutation proﬁles of a set of high-MAF mutations shared among at least two glands in the target-gene sequencing. Glands marked with an asterisk were
used for WGS. Color density indicates the MAF of each somatic mutation. d Sharing pattern of somatic SNVs based on WGS among 15 glands. Color
density indicates the MAF of each somatic mutation. e Phylogenetic tree for binary mutation proﬁles based on WGS. f CN-LOH at chromosome 10
encompassing PTEN. The proﬁle for a representative gland (No. 13 in region C) is shown. The region affected by CN-LOH is highlighted in light green. The
numbers separated by a colon are the major and minor copy numbers for the regions indicated by the arrows. g Chronological ages at which clonal
expansions occurred. The dashed line corresponds to the average of the proportion of public mutations to the overall mutational burden. h Bimodal
distributions of the MAFs of public mutations in the regions affected by two CN-LOHs. i Chronological ages at which two CN-LOHs occurred in the mutant
clones of cluster 3. j Schematic illustration of genomic evolution in the normal endometrium. MRCA, most recent common ancestor. Source data are
provided as a Source data ﬁle.

carcinoma59. As clonal hematopoiesis increases the risks for
blood cancer and cardiovascular disease10, there is a possibility
that the overrepresentation of endometrial glands derived from a
single clone raise the risks for endometrium-related diseases.
Long-term follow-up studies are needed to determine whether
mutant clones with cancer-associated gene mutations extends
their territories over time and whether the situation where the
population of endometrial epithelial cells is dominated by a small
number of mutant clones increases the risks for endometriumrelated diseases such as adenomyosis, endometriosis and endometrial cancer. Several lines of evidence shows that oral contraceptives decrease the risks for endometrial and ovarian cancers60
and endometriosis61. The biological mechanism behind these
preventive effects may be partially explained if we demonstrate
that the regulation of the menstrual cycle by oral contraceptives
alleviates the mutational burden and the aberrant proliferation of
the rhizome structure in the endometrium. Further efforts are
needed to unlock the mystery of the rhizome structures.
We demonstrated the somatic evolutionary dynamics of
mutant clones in the human endometrium at a microscopic
spatial resolution. Three-dimensional mapping of mutant clones
in the endometrium will illuminate the path toward a more
precise understanding of the mechanisms of endometrial regeneration during the menstrual cycle and the development of
therapies for the prevention and treatment of endometriumrelated diseases.
Methods
Human sample collection. This study was approved by the institutional ethics
review boards of Niigata University (G2017-0010 and G2019-0038), Nagaoka Chuo
General Hospital (331), National Institute of Genetics (29-15), and Sasaki Institute
(ER2020-04). We recruited study participants at the Niigata University Medical
and Dental Hospital and the Nagaoka Chuo General Hospital between December
2015 and September 2019. All subjects provided written informed consent for the
collection of samples and analyses, and for the publication of their clinical
information.
We collected 1087 single uterine endometrial gland samples from 32 patients
(aged 21–53 years) with no endometrial gynecological disease (Subject No. 1–32).
Among them, 196 glands were excluded at the quality control step of sequence data
analysis. The samples were from endometrial biopsies using suction catheters in
gynecological patients (n = 23) or endometrial curettage in patients undergoing
hysterectomy (n = 9). Endometrial suction was performed under lumbar
anesthesia or general anesthesia during surgery for gynecological disease.
Endometrial curettage was performed on surgically resected uteri using a
disposable scalpel. Diagnosis of the sample cases included myoma uteri (n = 11),
ovarian dermoid cyst (n = 7), adenomyosis or ovarian endometriosis (n = 9),
cervical intraepithelial neoplasia (CIN)3 or carcinoma in situ (CIS) (n = 5), cervical
cancer (n = 1) and ovarian clear cell carcinoma (n = 1) (there was some overlap).
Clinicopathological information is shown in Supplementary Table 1.
We performed multisegmental sampling for a total of four patients (aged 38–50
years) who underwent hysterectomy (Subject No. 33–36). Diagnosis of the sample
cases included myoma uteri (n = 2), ovarian endometriosis (n = 1), and CIN3 or
CIS (n = 1). We divided the endometrium into 7-48 segments and selected
451 single endometrial gland samples, with a sampling depth range of

3–20 samples per segment. The area of each segment was 6.25–25 mm2. Among
them, 44 glands were excluded at the quality control step of sequence data analysis.
Clinicopathological information is shown in Supplementary Table 2. For the 3D
imaging analysis, we collected four uterine endometrial samples from 30 to 52year-old premenopausal women who underwent hysterectomy (Subject No.
37–40). Diagnosis of the samples included myoma uteri (n = 2) or cervical cancer
IA1 (n = 1) or IB1 (n = 1). Clinicopathological information is shown in
Supplementary Table 3. For the WGS analysis using laser microdissected tissues,
we collected uterine endometrial samples from a 43-year-old premenopausal
woman who underwent hysterectomy because of endometriosis (Subject No. 41).
We conﬁrmed that the endometrial tissues collected from all the individuals
were clinically and histologically normal. Peripheral blood samples were also
collected from each patient and used as matched controls for the delineation of
somatic versus germline variations.

Isolation of single endometrial glands. The isolation of single endometrial glands
from bulk endometrial tissue was performed as described in our previous
studies15,29, with some modiﬁcations. Brieﬂy, minced fresh endometrial tissues,
consisting of endometrial glands and stroma, were placed in Dulbecco’s modiﬁed
Eagle’s medium (Thermo Fisher Scientiﬁc) containing 180 U/ml collagenase type 3
(Worthington Biochemical Corporation). After shaking gently at 37 °C for 40 min,
this solution of collagenase-digested tissue was poured into a 40-micron EASYstrainer (Greiner Bio-One), and cold phosphate-buffered saline (PBS) was poured
over the screen to wash away the digestion-loosened endometrial stromal cells. The
tissue remaining on the strainer, mostly epithelial cell glands, was transferred into a
cell culture dish. After gentle pipetting, the separated endometrial glands sank to
the bottom of the dish. Individual glands were picked up precisely under a
microscope. Each gland was collected into a 0.2 ml microtube containing ATL
buffer (QIAGEN) and stored at −80 °C until DNA extraction. A total of 1538
glands from 36 patients were used for target-gene sequencing analyses. Thirteen
glands from subject No. 34 and 15 glands from subject No. 35 were also used for
WES analysis. Thirteen glands from subject No. 36 were also used for WGS
analysis.

Laser-microdissection of each entire gland. All endometrial tissues were
immediately separated from the surgical specimen, embedded in Tissue-Tek O.C.T.
compound (Sakura Finetek) in a Tissue-Tek Cryomold (Sakura Finetek), frozen in
liquid nitrogen, and stored at −80 °C. We cut 12-µm-thick serial frozen sections
with a Cryotome FSE (Thermo Fisher Scientiﬁc) and mounted them on PENMembrane Slides (Leica).
For laser microdissection, the cryosections were ﬁxed with 100% methanol for
3 min and then stained with toluidine blue for 30 s. Before laser microdissection, all
images of cryosections were stored using the Specimen Overview function of the
LMD7 laser microdissection microscope (Leica) to assess glandular continuity. We
performed laser microdissection using LMD7 (Leica), distinguishing the vertical
and horizontal glands, which often branched from or connected with each other
(Fig. 7). The isolated epithelial tissues of each gland were collected in the caps of
0.2 ml PCR tubes (Axygen). The median number of frozen sections for sampling
each gland was 13 sections (range: 8-18).

DNA extraction. DNA extraction from the isolated endometrial glands and the
laser-microdissected glands was performed using a QIAamp DNA Micro Kit
(QIAGEN) according to the manufacturer’s protocol. Case-matched control DNA
was extracted from peripheral blood with a QIAamp DNA Blood Maxi Kit
(QIAGEN) according to the manufacturer’s instructions. All puriﬁed DNA samples
were stored at −80 °C until subsequent analyses.
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Fig. 6 3D imaging of normal proliferative endometrial tissue. a Microscopic hematoxylin- and eosin-stained images of endometrium obtained from a 52year-old woman (subject 40) with myoma uteri who underwent a total hysterectomy. Scale bar, 500 µm. b Reconstructed 3D image of the endometrial
tissue. The red object represents the 3D structure of the glands sharing a rhizome. c 3D and XY cross-sectional images capturing a rhizome structure that
runs horizontally along the muscular layer and gives rise to multiple vertical glands. From the reconstructed 3D image (left panel), XY cross-sectional
images (right panel) with a slice thickness of 200 µm are extracted. The XY slice is enclosed by orange. d 3D image quantifying the longest distance
between glands sharing the rhizome (red line) and the area occupied by the glands (light blue area). Red object: 3D image of the structures of the glands
sharing a rhizome. Yellow objects: the tips of the glands. 3D images were obtained by light-sheet ﬂuorescence microscopy. Autoﬂuorescence and CK7expressing endometrial epithelial cells were measured by excitation with 488 nm and 532 nm lasers, respectively. Red and yellow objects were made by
the Surface module in Imaris software. Autoﬂuo, autoﬂuorescence; CK7, cytokeratin 7. Source data are provided as a Source data ﬁle.
Target-gene sequencing. The target-gene sequencing of single endometrial glands
for 112 genes was performed as described in our previous studies with some
modiﬁcations15,59,62,63. Brieﬂy, 112 genes were selected (Supplementary Data)
based on WES data for ovarian endometriosis and normal uterine endometrium15,
the mutation proﬁles in endometriosis-related ovarian cancer64 and in endometrial
cancer48, and genes involved in DNA repair pathways65,66.
DNA samples were fragmented using a KAPA Frag Kit (KAPA Biosystems).
Sequencing libraries were constructed with a NEBNext Ultra II DNA Library Prep
Kit for Illumina (New England Biolabs). Libraries of up to 96 samples were pooled
in equimolar amounts and then hybridized to probes of a SeqCap EZ Prime Choice
System (Roche Diagnostics) in a single enrichment reaction. The DNA probe set
was selected by using NimbleDesign (Version 3.8) (http://design.nimblegen.com).
The quantity and size distribution of the captured libraries were assessed by a
Qubit 2.0 Fluorometer (Thermo Fisher Scientiﬁc) and Bioanalyzer 2100 (Agilent
Technologies), respectively. The libraries were then sequenced via the Illumina
HiSeq 2500, HiSeq 4000 or NovaSeq 6000 platform with 2×100-bp or 2×150-bp
paired-end modules (Illumina).
12

Data preprocessing. As a quality control step, the Illumina adapter sequences
were trimmed by using Trim Galore (Version 0.6.3) (https://
www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Low-quality sequences were excluded or trimmed with Trimmomatic (Version 0.39)67. The ﬁltered
sequence reads were aligned to the human reference genome (GRCh38) containing
sequence decoys and virus sequences generated by the Genomic Data Commons
(GDC) of the National Cancer Institute (NCI) using BWA-MEM (Version
0.7.17)68,69. The sequence alignment map (SAM) ﬁles were sorted and converted to
the binary alignment map (BAM) ﬁle format with SAMtools (Version 1.9)70. The
BAM ﬁles were processed using Picard tools (Version 2.20.6) (http://
broadinstitute.github.io/picard/) to remove PCR duplicates. Base quality recalibration was conducted using GATK (Version 4.1.3.0)71,72. The average depths and
the coverages of the target regions were calculated with SAMtools. BEDOPS
(Version 2.4.36)73 and BEDTools (v2.28.0)74 were used in the handling of FASTA,
VCF and BED ﬁles.
We used endometrial glands for subsequent analyses if more than 70% of the
target bases were covered by at least 20 reads. For 32 subjects used in the analyses
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of mutational burden, mutational signatures and selections acting on cancerassociated gene mutations, the means of the average sequencing depth and the
coverage at ≥20 reads for the target regions were 87.7 and 93.5%, respectively. For
four subjects used in the analysis of spatially resolved single endometrial gland
sequencing, the means of the average sequencing depth and the coverage at ≥20
reads for the target regions were 80.9 and 93.1%, respectively.

Variant calling. Somatic SNVs and short indels were called in each pair of
endometrial gland and matched blood samples by using Strelka2 (Version

30

1.00

40

Private

2.9.10)75. For somatic indel calling, we utilized the information about candidate
indel sites provided by Manta (Version 1.6.0)76. The variants whose empirical
variant scores provided by Strelka2 were greater than 13.0103 (= −10 × log10 0.05)
were used for subsequent analyses. In addition, we excluded variants whose frequencies were greater than or equal to 0.001 in any of the general populations from
the 1000 Genomes Project77, the National Heart, Lung, and Blood Institute
(NHLBI) GO Exome Sequencing Project78, and the Genome Aggregation Database
(gnomAD)79 to prevent false-positive variant calls. Functional annotations for the
protein-coding and transcription-related effects of the identiﬁed variants were
implemented by Ensembl Variant Effect Predictor (VEP)80. Curated information

NATURE COMMUNICATIONS | (2022)13:943 | https://doi.org/10.1038/s41467-022-28568-2 | www.nature.com/naturecommunications

13

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28568-2

Fig. 7 Genomic evolution of endometrial glands connected through rhizome structures. a Toluidine blue-stained images of endometrial glands from a 43year-old woman after laser microdissection. Scale bar, 500 µm. b Evaluation of the continuity between glands by serial section images before laser
microdissection. Top images, continuity between glands 1 and 6. Middle and bottom images, continuity between glands 8 and 11. Scale bar, 300 µm. c
Schematic illustration of glands isolated by laser microdissection. According to their continuity, the ﬁrst group (rhizome: G1, and vertical glands: G2 to G7),
the second group (rhizome: G8, and vertical glands: G9 to G12), and an independent vertical gland (G13) are color-coded in red, yellow, and light blue,
respectively. d Reconstructed 3D image of glands isolated by laser microdissection, based on serial section images. The color code assignment is as
described in (c). e Sharing pattern of somatic SNVs based on WGS among 13 glands. Color density indicates the MAF of each somatic mutation. f Heatmap
of the prevalence of representative cancer-associated gene mutations in 13 glands. Color density indicates the MAF of each somatic mutation. g Fish plots
showing the clonal evolution of 11 mutant clones (A-K) within 13 glands. h Branch-based consensus clonal evolution tree of 11 mutant clones (A-K) among
13 glands. Nodes and edges correspond to mutant clones and somatic mutations accumulated during evolution between the connected clones,
respectively. The identiﬁers of glands are indicated beside a node if the clone was observed in the corresponding glands at the time when the sample was
taken. i Chronological ages at which clonal expansions occurred in mutant clones of the ﬁrst and second groups of glands. The dashed line corresponds to
the average proportion of public mutations to the overall mutational burden in each cluster. Source data are provided as a Source data ﬁle.

about cancer-associated genes and their functional roles in cancer development was
retrieved from the COSMIC database38.
Mutational signature analysis. We used the identiﬁed somatic SNVs with high
MAF (≥0.25) from the 32 subjects for mutational signature analysis. The somatic
SNVs with high MAF were classiﬁed into 96 mutation classes deﬁned by the six
pyrimidine substitutions (C>A, C>G, C>T, T>A, T>C, and T>G) in combination
with the ﬂanking 5′ and 3′ bases. In our mutational signature analysis, we ﬁtted the
96-mutation catalog to a predeﬁned list of known signatures81,82. We did not select
an approach for de novo signature extraction because the number of somatic
mutations was not large enough in this study. As a reference set of known
mutational signatures, we used the COSMIC mutational signatures version 334. We
selected a total of eleven SBS signatures (SBS1, SBS2, SBS3, SBS5, SBS10a, SBS10b,
SBS13, SBS15, SBS18, SBS40, and SBS44) whose activities were estimated to be
present in at least 10% of samples in any of three gynecologic cancers (cervical
cancer, endometrial cancer and ovarian cancer) based on the COSMIC mutational
signatures (https://cancer.sanger.ac.uk/cosmic/signatures/). We implemented a
ﬁtting approach by using sigﬁt83. We ran four Markov chains with a total of 50,000
iterations, including a burn-in of 25,000 samples. We estimated the highest posterior density (HPD) interval for each of the SBS signatures. If the 90% lower end
of the HPD interval for a SBS signature was above the threshold (0.01, default
value), we considered that the SBS signature was a signiﬁcantly active signature.
Calculation of mutational burden. Mutational burden (bi ) was calculated for the i
th subject over endometrial glands as follows:
bi ¼ ∑j nij ´ 106 =∑j lij ;

ð1Þ

where nij and lij are the number of somatic mutations and the number of bases
within the target region that were covered by at least 20 reads in the j th gland of i
th subject, respectively. We assessed the association between the burden of somatic
mutations and the clinical features of the subjects (Supplementary Table 1). The
Pearson correlation coefﬁcient and one-way analysis of variance were used for
quantitative and categorical clinical variables, respectively. Linear regression analysis was conducted to assess the effects of clinical features on the burden of
somatic mutations with adjustment for age. The statistical tests were performed as
two-tailed tests using the stats package of the R software (https://www.Rproject.org/).
Calculation of the burden of driver mutations. We selected cancer driver genes
that were included in the Cancer Gene Census40 and the pan-gynecologic cancerassociated genes41 from the 112 genes (Supplementary Data). As a result, the nine
genes were selected: ARID1A, CTNNB1, FBXW7, KRAS, PIK3CA, PIK3R1,
PPP2R1A, PTEN, and TP53. The burden of driver mutations is deﬁned as the
number of non-silent mutations in these nine genes per gland in each subject. The
difference in the average age or CNMCs between carriers of KRAS mutations
exhibiting allelic imbalance (MAF ≥ 0.8) and non-carriers was examined by Wilcoxon rank-sum test with the exactRankTests package of the R software.
Identiﬁcation of genes under positive and negative selection. We searched for
genes under the pressures of positive and negative selection based on the dN/dS
ratio. To estimate the dN/dS ratio, we patterned our approach after the Poisson
framework developed by previous studies39,84. We modeled the numbers of SNVs
n
s
resulting in missense (nm
i ), nonsense (ni ) and synonymous (ni ) substitutions in the
i th trinucleotide context as follows:


m
m
;
ð2Þ
nm
i  Poisson λ ¼ t ´ r i ´ Li ´ ω


nni  Poisson λ ¼ t ´ r i ´ Lni ´ ωn ;
14

ð3Þ



nsi  Poisson λ ¼ t ´ r i ´ Lsi ;

ð4Þ

where t is the baseline substitution rate per site, r i is the relative substitution rate in
the i th trinucleotide context, Li is the number of sites at which the i th substitution
results in (m)issense, (n)onsense, and (s)ynonymous mutation, and ω is the dN/dS
ratio. The number of identiﬁed somatic mutations in this study was not large
enough to estimate substitution rates in trinucleotide contexts. Therefore, we relied
on the COSMIC database as an unbiased catalog of somatic mutations. We
downloaded the ﬁle “CosmicNCV.tsv” of v94 (May 2021). First, we retrieved noncoding somatic SNVs from the ﬁle by using the following ﬁltering criteria: (i)
inclusion of SNVs conﬁrmed to be somatic, and (ii) exclusion of known single
nucleotide polymorphisms. Then, we selected the SNVs if the primary site of the
sample with the SNV was cervix, endometrium or ovary. As the consequence,
about 1.1 million somatic SNVs in noncoding regions from the COSMIC database
were classiﬁed into 96 mutation classes constituted by the six pyrimidine substitutions in combination with the ﬂanking 5′ and 3′ bases. Then, the relative
substitution rate for each trinucleotide context (r i ) was calculated. The baseline
substitution rate per site (t) was selected to satisfy the following equation:
j

j

∑i ∑j2fm;n;sg ni ¼ ∑i ∑j2fm;n;sg t ´ r i ´ Li :

ð5Þ

The values nm , nn and ns were evaluated for several sets of genes or for each
gene. We considered three sets of genes: (i) all 112 genes, (ii) 48 genes included in
the Cancer Gene Census40, and (iii) 15 genes included in the pan-gynecologic
cancer-associated genes41. Poisson regression analysis was implemented, where nm
(or nn ) and ns were modeled by including the log-transformed value of their
expected numbers (i.e., ∑i t ´ r i ´ Li ) as the offset and the ω term. When examining
the sets of genes, the signiﬁcance of ω was assessed by Poisson regression analysis.
According to a previous study39, the fraction of genuine driver mutations in a
group of genes was calculated as follows: f ¼ ðω  1Þ=ω.
When the signatures of positive selection were evaluated at the level of
individual genes, we identiﬁed 27 genes with at least ﬁve SNVs with high MAF in
their coding sequences. Additionally, we considered genes if the observed numbers
of missense or nonsense mutations (nm or nn ) were larger than their expected
numbers calculated by using t, r i and Li . Then, the likelihood ratio test was
conducted to compare the two Poisson regression models with and without the ω
term. To account for multiple hypothesis testing, genes satisfying a false discovery
rate based on Benjamini–Hochberg procedure < 0.1 were considered to be
signiﬁcant85. The Poisson regression analyses were performed by the glm function
from the MASS package in the R environment.
Analyses of spatially resolved single endometrial gland sequencing. To
evaluate the extent to which somatic mutations were shared between glands located
in spatially separated regions of the endometrium, we compiled MAF proﬁles of all
the mutation sites for all the glands by counting the sequence reads supporting the
reference and mutant alleles with SAMtools mpileup70. For this analysis, the reads
mapped with high conﬁdence (mapping quality > 30) were used. Then, the allelespeciﬁc counts were measured by using only high-conﬁdence base calls (base
quality > 20) at the mutation sites. We excluded sites whose MAFs in the matched
blood sample exceeded 0.05. We selected informative mutations based on the
following criteria: (i) a set of mutations that were shared among a group of glands
at MAF of greater than or equal to 0.10; and (ii) mutations with MAF values
greater than or equal to 0.25 in at least two glands. The MAF proﬁles of the
informative mutation sites were analyzed by hierarchical clustering analysis with
the superheat R package86.
Experimental procedures for WES and WGS. The libraries were prepared as
described above. For WES, we used a hybridization capture method with IDT xGen
Exome Research Panel v2 (IDT xGen Exome Research Panel v2 (Integrated DNA
Technologies), in which precapture libraries from at most six samples were pooled
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and then hybridized in a single enrichment reaction. For the WGS of endometrial
glands isolated by laser microdissection, DNA samples were repaired by using
NEBNext FFPE DNA Repair Mix (New England Biolabs). The precapture libraries
were prepared as described above and used for a subsequent sequencing step. The
libraries were sequenced via the Illumina NovaSeq 6000 platform with a 2 × 150-bp
paired-end module (Illumina).
Bioinformatics pipeline for WES and WGS. In WES, we used target regions in
the BED format provided by the manufacturer. The means of the average
sequencing depth and the coverage at ≥10 reads for the target bases over 30 WES
data were 49.0 and 96.6%, respectively.
To ﬁlter somatic mutations in WGS, we used a “universal mask” outlined in
previous studies87–89. The universal mask encompasses regions in which false
positive variants are recurrently detected. Low-complexity regions in the human
reference genome (GRCh38) were determined by mdust (https://github.com/lh3/
mdust). DNA satellites and low complexity regions were based on the RepeatMasker
track from the UCSC Genome Browser (https://genome.ucsc.edu/). Homopolymeric
stretches (≥7 bp) were sought by seqtk (https://github.com/lh3/seqtk). The lowmappability mask was generated by following the SNPable Regions procedure
(http://lh3lh3.users.sourceforge.net/snpable.shtml). Brieﬂy, at each position in the
human reference genome (GRCh38), all possible 75-mers overlapping the position
were extracted and mapped back to the reference genome with BWA. Low
mappability regions were deﬁned as genomic positions for which 37 or fewer
overlapping 75-mers were mapped elsewhere with at most one mismatch or gap.
The means of the average sequencing depth and the coverage at ≥10 reads for the
target bases over 30 WGS data were 27.2 and 96.1%, respectively.
To identify somatic variants with high conﬁdence, we used the following
criteria: (i) the empirical variant score provided by Strelka2 was greater than
13.0103; (ii) the frequencies in the abovementioned general populations were
smaller than 0.001; (iii) the sequencing depth was greater than or equal to 20; (iv)
eight or more reads supported the mutant allele; (v) the MAF was greater than or
equal to 0.25; and (vi) the MAF in the matched blood sample did not exceed 0.05.
Detection of somatic copy number alterations. Somatic copy number alterations
were sought by using FACETS based on the information about the total sequence
read count and allelic imbalance in endometrial glands and the matched blood
samples90. Germline polymorphic sites were retrieved from the VCF ﬁle generated
by the 1000 Genomes Project77. The absolute value of the log odds ratio of the
variant allele read count in the gland and blood pair was used as the degree of
allelic imbalance. After excluding the regions affected by somatic copy number
alterations, the mean of the absolute value of the log odds ratio over the germline
heterozygous SNVs in the genome was calculated. Then, the mean was subtracted
from each of the absolute value of the log odds ratio to normalize the data to have a
mean of zero. Finally, the moving averages of the normalized absolute value of the
log odds ratio over 100 heterozygous SNVs were calculated and used for the
visualization.
Reconstruction of phylogenetic trees. Based on the binary mutation proﬁle
according to the presence or absence of somatic SNVs, genetic distances between
endometrial glands were computed as the pairwise Hamming distance. The
neighbor joining method and the maximum parsimony method were used to
reconstruct phylogenetic relationships between the endometrial glands in each
subject by using the APE and phangorn packages in the R environment91–93.
Identiﬁcation of putative clonal populations. The clonal populations present in
endometrial glands were explored by clustering somatic SNVs with PyClone 46.
The SNVs were selected by the following criteria: (a) the depth was greater
than or equal to 10 in all endometrial glands from a patient; (b) the MAF was
greater than or equal to 0.25 in at least one endometrial gland; (c) the mutations did not overlap with the somatic copy number alterations detected by
FACETS; and (d) SNVs with low MAF (<0.1) in multiple samples were
excluded as putative false positives. In WES, we excluded TTN, MUC3A,
TAS2R19, TAS2R31, EDEM2, PABPC3, and OR8U1 because the SNVs in these
genes had low MAF values, and the mutant alleles were found in the matched
blood sample, indicating false-positive variant calls. For the mutation sites
satisfying these criteria, we compiled MAF proﬁles of all the mutation sites for
all the glands by counting the sequence reads supporting the reference and
mutant alleles as described above. The MAF proﬁles were used for PyClone.
Then, clusters with ≥15 mutations were used for subsequent analysis. Then, the
results of the SNV clustering together with their MAFs were used as the input
to ClonEvol 47. The polyclonal seeding model was implemented. The number of
bootstrap samples was set to 10,000.
Estimation of timing of genomic events. Motivated by previous studies43,44, we
estimated the timing of clonal expansions and somatic copy number alterations.
The somatic SNVs detected in each group or cluster of glands in a subject were
divided into three types: (i) public mutations shared by all glands in a group or
cluster, (ii) partially shared mutations shared by a part of the glands in a group or
cluster, and (iii) private mutations that were detected only in single glands. Public

mutations are thought to precede the most recent clonal expansion that gave rise to
a group or cluster of glands followed by diversifying events, including partially
shared mutations and subsequent private mutations. We assumed that the mutation rate for somatic SNVs differed across groups or clusters of glands but
remained constant between birth and age at sampling. By using somatic SNVs in
regions that were not affected by somatic copy number alterations, the timing of
the most recent clonal expansion was estimated as the age at sampling multiplied
by the proportion of public mutations to the overall mutational burden in the
respective group or cluster of glands as follows:


T CE ¼ Age ´ MBpub = MBpub þ MBps þ MBpriv :
ð6Þ


Let m ¼ MBpub þ MBps þ MBpriv and p ¼ MBpub = MBpub þ MBps þ MBpriv ,
qﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ﬃ


95% CI of p was calculated as: p ± 1:96 ´ p 1  p =m.
Next, we analyzed the timing of two CN-LOH events at chromosomes 3 and 10
in the endometrium of a subject, which were detected by FACETS. We sought
public mutations in the regions affected by these two events. In principle, the MAFs
of public mutations that occurred before a CN-LOH are expected to be 1, whereas
the MAFs of public mutations that occurred after CN-LOH are expected to be 0.5
when the cellular fraction of the CN-LOH (ρ) is 1. We computed the joint
probabilities of observing d mut
i;j reads supporting the mutant allele in sequence
depth d i;j at the j th public SNV site (j ¼ 1; ¼ ; l) in the i th gland (i ¼ 1; ¼ ; n)
pre
post
given that the public SNV occurred before (Pj ) or after (Pj ) a CN-LOH as
follows:
!
n
Y
d i;j
dref
d mut 
pre
Pj ¼
´ ρi i;j ´ 1  ρi i;j ;
ð7Þ
mut
d
i;j
i¼1
and
post

Pj

¼

n
Y

d i;j

i¼1

d mut
i;j

!
´

ref
ρ dmut

ρ di;j
i i;j
´ 1 i
;
2
2

ð8Þ

ref

where d i ¼ d i  d mut
i . The value of ρi was estimated for each gland by FACETS.
Then, the relative ratios of these
were used asthe weights for the
 joint probabilities

pre

j th public SNV: wj

pre

pre

post

¼ Pj = Pj þ Pj

post

and wj

post

¼ Pj

pre

post

= Pj þ Pj

.

In order to estimate the timing of the CN-LOH and its 95% CI by incorporating
the uncertainty of the assignments of the SNVs to before or after the CN-LOH
event, we conducted a simple simulation study with 10,000 iterations. By
generating random numbers between 0 and 1, we assigned whether each of the
variants occurred
before or after the CN-LOH

 event based
 on the probabilities:
pre

wj

pre

pre

post

¼ Pj = Pj þ Pj

post

and wj

post

¼ Pj

pre

post

= Pj þ Pj

. The mutational

burdens before and after the CN-LOH were MBpre ¼ 2 ´ number of somatic SNVs
occurred before the CN-LOH and MBpost ¼ number of somatic SNVs occurred
after the CN-LOH, respectively. Somatic SNVs that occurred before the CN-LOH
resided on the retained allele, and somatic SNVs on the other allele were lost
during the CN-LOH. This indicates that the number of somatic SNVs was expected
to decrease by half. Therefore, we doubled the number
 of SNVs occurred before
CN-LOH. The proportion MBpre = MBpre þ MBpost

and its variance were

calculated for each iteration. Let m ¼ MBpre þ MBpost and




p ¼ MBpre = MBpre þ MBpost , the variance of p was calculated as: p 1  p =m.
Next, we estimated the timing of the CN-LOH as follows:


ð9Þ
T CNLOH ¼ T CE ´ MBpre = MBpre þ MBpost :




Let MBpub = MBpub þ MBps þ MBpriv and MBpre = MBpre þ MBpost be X and
Y, respectively, the variance of XY can be written as:
V ðXY Þ ¼ V ð X ÞV ðY Þ þ Eð X Þ2 V ðY Þ þ EðY Þ2 V ð X Þ. Based on the variance, we
calculated the 95% upper and lower limits of T CNLOH in each iteration. After the
simulation study, the means over the 10,000 iterations were calculated as the
estimate for T CNLOH and its 95% CI.
Visualization for statistical analyses and distribution of somatic mutations.
The R packages, ggplot2 (Version 3.3.3), ggjoy (Version 0.4.1) and ggridges
(Version 0.5.3), were used to visualize the results of statistical analyses. The
mutational spectrum was depicted by the barplot3d R package (Version 1.0.1). The
lolipop plots displaying mutation distribution and protein domains were created by
the trackViewer R package (Version 1.22.1).
Whole-mount 3D staining of endometrial tissue. For the whole-mount 3D
staining of human endometrial tissue, we used the updated clear, unobstructed
brain/body imaging cocktails and computational analysis (CUBIC) protocols
described in our previous studies31,45. Brieﬂy, endometrial blocks (55 to 635 mm3)
were stored in formalin until use. The tissue blocks were washed with PBS for 6 h
before clearing. Then, the tissue blocks were immersed in CUBIC-L [T3740
(mixture of 10 wt% N-butyldiethanolamine and 10 wt% Triton X-100), Tokyo
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Chemical Industry] with shaking at 45 °C for 6 days. During delipidation, the
CUBIC-L was refreshed once. After the samples were washed with PBS for several
hours, the tissue blocks were placed in 1 ml of immunostaining buffer (mixture of
PBS, 0.5% Triton X-100, 0.25% casein, and 0.01% NaN3) containing 1:100 diluted
Alexa 555-conjugated CK7 antibody (ab203434, Abcam) for 14 days at room
temperature with gentle shaking. After washing again with PBS for several hours,
the samples were then subjected to postﬁxation by 1% PFA in 0.1 M PB at room
temperature for 5 hours with gentle shaking. The tissue samples were immersed in
1:1 diluted CUBIC-R+ [T3741 (mixture of 45 wt% 2,3-dimethyl-1-phenyl-5pryrazolone, 30 wt% nicotinamide and 5 wt% N-butyldiethanolamine), Tokyo
Chemical Industry] with gentle shaking at room temperature for 1 day. The tissue
samples were then immersed in CUBIC-R+ with gentle shaking at room temperature for 2 days.
Microscopy. Macroscopic whole-mount images were acquired with a light-sheet
ﬂuorescence (LSF) microscope (MVX10-LS, Olympus) using a ×0.63 objective lens
[numerical aperture = 0.15, working distance = 87 mm] with digital zoom ×3.2.
Voxel resolution was set as follows: x = 3.27 µm, y = 3.27 µm, and z = 5.0 µm. The
LSF microscope was equipped with lasers emitting at 488 nm and 532 nm. When
the stage was moved in the axial direction, the detection objective lens was synchronically moved to the axial direction to prevent defocusing. The
Alexa555 signals of CK7-expressing endometrial epithelial cells were measured by
excitation with 532 nm lasers. Autoﬂuorescence was measured by excitation at
488 nm.
3D image analysis. All raw image data were collected in lossless 16-bit TIFF
format. All CK7 ﬂuorescence images were obtained by subtracting the background
and applying an unsharp mask using Fiji software94. Three-dimensionally rendered
images were visualized, captured and analyzed with Imaris software (Version 9.5.1,
Bitplane). The image analysis by Imaris software was performed as described in our
previous study31. Brieﬂy, TIFF ﬁles were imported in the Surpass mode of Imaris.
The reconstituted 3D images were cropped to a region of interest using the 3D
Crop function. Using the channel arithmetic function, the CK7 signal was removed
from the autoﬂuorescence signal to create a channel with only endometrial epithelium and gland signals. To identify glandular continuity, we observed the shapes
of glands using continuous tomographic images from the XY, XZ, and YZ planes.
Then, we selected one unit of the glands sharing the rhizome. The glands sharing
the rhizome were traced manually, and their 3D structures were reconstructed by
the Surface module. The 3D surface object was pseudocolored and separated into a
new channel. Thus, the glands sharing the rhizome were visualized. To calculate
the surface area of the endometrium occupied by the openings of the glands
sharing a rhizome, the XYZ coordinates of the tips of the glands of the 3D surface
objects were measured using the Measurement Point module. We formed triangles
by selecting three points of the tips of the glands so that the resulting triangles did
not overlap with each other. Then, the surface area was calculated as the sum of the
areas of the triangles. Among the surface areas for all possible combinations of the
triangles, the smallest one was selected. Because subject No. 40 had a large number
of glands sharing the rhizome, six glands located on the outside edge were selected.
The snapshot and animation functions were used to capture images and videos,
respectively.
3D modeling of laser-microdissected glands. To create the 3D model of laser
microdissected glands, 62 serial cryosection images before laser microdissection
were imported into Photoshop 2020 (Adobe). The ﬁrst image in the image stack
was selected as a reference image and used to align subsequent images. Thus, all
images were aligned to their neighbors. The shapes of endometrial glands were
drawn manually in new layers with a transparent background on each 2D serial
cryosection image, which were exported individually as TIFF images. Threedimensionally rendered images were visualized and captured with Imaris software
(Version 9.5.1, Bitplane) as mentioned above. Brieﬂy, TIFF ﬁles were imported in
the Surpass mode of Imaris. Using the channel arithmetic function, the signals of
the gland depicted were distinguishable from the background and used for 3D
reconstruction by the Surface module. The snapshot and animation functions were
used to capture images and videos, respectively.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

microdissection microscope and 3D images are available at https://true.med.niigatau.ac.jp/ncomm2021/. Source data are provided with this paper.

Code availability
Code for statistical analyses on mutation burden, mutational signatures, and timing of
genome events including clonal expansions and copy neutral loss-of-heterozygosity is
deposited on GitHub at https://github.com/HirofumiNakaoka/
endometrium_natcommun_2021.
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